Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK 249553 (MAGE-A3 vaccine) in resected NSCLC
NCT00290355Phase 2Completed
- Sponsor
- GSK
- Start
- May 2002
- Primary completion
- Jul 2011
- Modality
- Vaccines & Immunotherapeutics, Peptides, Fc-Fusion Proteins
- Countries
- 14
01
Overview
A Phase 2 trial of astuprotimut-R in non-small cell lung cancer (NSCLC), sponsored by GSK. Started May 2002; status: completed.
02
Drugs
astuprotimut-R
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00290355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00290355.